Abstract
Pulmonary delivery of the decapeptide detirelix was studied in briefly anesthetized dogs and the pharmacokinetics were examined following intravenous administration, intratracheal instillation, and aerosol inhalation. Detirelix administrations to the lung gave plasma profiles that were extended over two days, and that differed markedly from those of similarly sized peptides. Absorption from the lung after instillation was slow (Tmax= 6.5 ± 3.6 h) with a relative bioavailability of 29 ± 10%. Administration of detirelix-containing aerosols resulted in similar plasma profiles as for administration by instillation. Compartmental and non-compartmental methods of pharmacokinetic analysis indicated no faster absorption from aerosols than from instilled solutions; an absorption rate limiting process may be an explanation. Plasma profiles were not affected by the use of detirelix liquid crystal favoring formulations or destabilizing formulations, and suggested that in situ liquid crystal formation was not an explanation for the slow absorption. No significant changes in pharmacokinetics or systemic uptake were observed during the five-month period of repeated pulmonary administrations. Histopathologic examination revealed the lungs to be essentially normal.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
S. N. Pavlou, G. B. Wakefield, D. P. Island, P. G. Hoffman, M. E. Le Page, R. L. Chan, C. A. Nerenberg, and W. J. Kovacs. Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men. J. Clin. Endocrinol. Metab. 64:931–936 (1987).
R. L. Chan, W. Ho, A. S. Webb, J. La Fargue, and C. A. Nerenberg. Disposition of detirelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and monkeys. Pharm. Res. 5:335–340 (1988).
K. G. Bensch and E. A. M. Dominguez. Studies on the pulmonary air-tissue barrier. Part IV: Cytochemical tracing of macromolecules during absorption. Yale J. Biol. Med. 43:236–241 (1971).
J. Gil. Number and distribution of plasmalemmal vesicles in the lung. Fed. Proc. 42:2414–2418 (1983).
S. J. Enna and L. S. Schanker. Absorption of saccharides and urea from the rat lung. Am. J. Physiol. 222:409–414 (1972).
D. Simionescu and M. Simionescu. Differentiated distribution of the cell surface charge on the alveolar-capillary unit. Microvascular Res. 25:85–100 (1983).
M. C. Williams. Endocytosis in alveolar type II cells: Effect of charge and size of tracers. Proc. Natl. Acad. Sci. USA 81:6054–6058 (1984).
M. F. Powell, L. M. Sanders, A. Rogerson, and V. Si. Parenteral peptide formulations: Chemical and physical properties of native luteinizing hormone-releasing hormone (LHRH) and hydrophobic analogues in aqueous solution. Pharm. Res. 8:1258–1263 (1991).
J. Fleitman, M. F. Powell, L. M. Sanders, and V. C. Si. Peptide liquid crystals: Inverse correlation of kinetic formation and thermodynamic stability in aqueous solutions. Pharm. Res. (Submitted).
D. B. Bennett, E. Tyson, S. Mah, J. S. de Groot, S. Terao, S. Hegde, and Z. Teitelbaum. Sustained delivery of detirelix after pulmonary administration of liposomal formulations. J. Contr. Rel. (Submitted).
C. Nerenberg, J. La Fargue, A. Webb, R. Chan, and S. Kushinsky. Radioimmunoassay of detirelix ([N-Ac-D-Nal(2)1, D-p-Cl-Phe2, D-Trp3, D-hArg(Et)2 6, D-Ala10]-luteinizing hormone-releasing hormone) in plasma or serum. J. Immunoassay 9:245–255 (1988).
L. Z. Benet and R. L. Galeazzi. Noncompartmental determination of the steady-state volume of distribution. J. Pharm. Sci. 68:1071–1074 (1979).
M. Gibaldi and D. Perrier. Pharmacokinetics, Marcel Dekker, Inc., New York, 1982, pp. 103–109.
D. J. Cutler. Theory of the mean absorption time, an adjunct to conventional bioavailability studies. J. Pharm. Pharmacol. 30:476–478 (1978).
D. Bennett, J. La Fargue, C. Nerenberg, R. Maskiewicz, L. Wood, and Z. Teitelbaum. Sustained plasma levels of detirelix following intratracheal instillation to anesthetized dogs. Pharm. Res. 9:S201 (1992).
A. Adjei, R. Doyle, M. Pratt, R. Finley, and E. Johnson. Bioavailability of leuprolide following intratracheal administration to beagle dogs. Int. J. Pharm. 61:135–144 (1990).
L. S. Schanker, E. W. Mitchell, and R. A. Brown. Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection. Drug Metab. Dispos. 14:79–88 (1986).
H. G. Folkesson, B. R. Weström, and B. W. Karlsson. Permeability of the respiratory tract to different-sized macromolecules after intratracheal instillation in young and adult rats. Acta Physiol. Scand. 139:347–354 (1990).
F.-Y. Liu, Z. Shao, D. O. Kildsig, and A. K. Mitra. Pulmonary delivery of free and liposomal insulin. Pharm. Res. 10:228–232 (1993).
R. M. Effros and G. R. Mason. Measurements of pulmonary epithelial permeability in vivo. Amer. Rev. Resp. Dis. 127:S59–S65 (1983).
H. Schreier, K. J. McNicol, D. B. Bennett, Z. Teitelbaum, and H. Derendorf. Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep. Pharm. Res. 11(7):1056–1059 (1994).
Y. Berthiaume, V. C. Broaddus, M. A. Gropper, T. Tanita, and M. A. Matthay. Alveolar liquid and protein clearance from normal dog lungs. J. Appl. Physiol. 65:585–593 (1988).
G. J. Burckart, R. Dowling, M. Zenati, S. A. Yousem, R. Venkataramanan, and B. P. Griffith. Cyclosporine administration by aerosol. J. Clin. Pharmacol. 29:860 (1989).
R. J. King and J. A. Clements. Surface active materials from the dog lung. I. Method of isolation. Am. J. Physiol. 223:707–714 (1972).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bennett, D.B., Tyson, E., Nerenberg, C.A. et al. Pulmonary Delivery of Detirelix by Intratracheal Instillation and Aerosol Inhalation in the Briefly Anesthetized Dog. Pharm Res 11, 1048–1055 (1994). https://doi.org/10.1023/A:1018999707476
Issue Date:
DOI: https://doi.org/10.1023/A:1018999707476